新型降糖药那格列奈的药理作用和临床应用  

Pharmacological and clinical development of a novel hypoglycemic agent: nateglinide

作　　者：黄晓程[1] 贤晓丽[1] 

机构地区：[1]山东威海市立医院老年病科,山东威海264200

出　　处：《中国新药与临床杂志》2005年第2期148-150,共3页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：那格列奈是一种新型的非磺酰脲类促胰 岛素分泌的降糖新药,其起效快且作用时间较短。 单用可有效控制餐时血糖增高,降低餐后血糖高峰, 与双胍类药物联合应用可发挥协同作用,治疗中、重 度高血糖症。那格列奈安全性、耐受性良好,极少发 生低血糖,几乎不影响病人体重。Nateglinide is a novel non-sulfonylurea antidiabetic agent by stimulating insulin secretion. Its action occurs rapidly and sustains shortly. It can effectively control mealtime glucose excursions and reduce the peak of postprandial hyperglycemia during single administration. It has synergistic effect with metformin for treating moderated or severe hyperglycemia. Nateglinide is safe and well tolerated with nearly no affects on the body weight of patients and rarely occurrence of hypoglycemia.

关 键 词：糖尿病 非胰岛素依赖型 降血糖药 低血糖症 那格列奈 

分 类 号：R587.1[医药卫生—内分泌] R977.15[医药卫生—内科学]